Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

Inclusion Criteria

• •Metastatic triple negative breast cancer with confirmation of Estrogen Receptor (ER) and HER2 negativity on a histological biopsy of a metastatic lesion
• •18 years or older
• •Metastatic lesion accessible for histological biopsy (Mandatory biopsies: pre-induction treatment, post-induction treatment, 6-weeks. Optional biopsies: 12-weeks, at progression, of irradiated site). The pre-induction treatment biopsy has to contain sufficient tumor content (≥100 tumor cells); subjects with samples that have insufficient tumor content will require re-biopsy prior to induction treatment. Interval between last treatment and pre-induction biopsy has to be at least 14 days
• •One, two or three line(s) of chemotherapy for metastatic disease and with progression of disease on last treatment regimen
• •Evaluable disease according to RECIST 1.1
• •Metastatic lesion accessible for radiation with 1x20 Gray or 3x8 Gray
• •WHO performance status of 0 or 1
• •Adequate bone marrow function
• •Adequate hepatic function
• •Adequate renal function
• •Signed written informed consent